Daniel Shu

Dr. Daniel Shu is an Assistant Professor in the Department of Medicine at the University of Maryland School of Medicine and a medical oncologist at the University of Maryland Greenebaum Comprehensive Cancer Center. His clinical expertise encompasses gastrointestinal cancers, including liver, bile duct, gallbladder, pancreas, and colon malignancies.

Education:

• MD from Temple University School of Medicine (2017)
• Internal Medicine Residency at Johns Hopkins Hospital (2020)
• Medical Oncology Fellowship at Johns Hopkins Hospital (2024)

Dr. Shu's research centers on cancer immunology, with emphasis on adaptive immune responses to malignancies. He employs multiomic techniques including bulk/single-cell RNA sequencing, TCR/BCR sequencing, and imaging mass cytometry to investigate tertiary lymphoid structures in liver cancer immunotherapy. His work bridges clinical oncology and mechanistic immunology to optimize therapeutic strategies.

His 2024-2025 publications reveal a concentrated focus on tertiary lymphoid structures as biomarkers and therapeutic targets in hepatocellular carcinoma. Research spans clinical trial analysis, pathological response assessment, and morphological characterization of immune structures during neoadjuvant immunotherapy, establishing foundational insights for precision immuno-oncology.

Scientific Awards:

• Conquer Cancer/ASCO Young Investigator Award (2024-2025)

Supported by the ASCO Young Investigator Award, Dr. Shu leads research integrating clinical oncology with advanced immunological profiling. He actively collaborates within multidisciplinary teams at the Greenebaum Comprehensive Cancer Center, focusing on gastrointestinal malignancies and immune microenvironment dynamics. His ongoing projects include biomarker development for immunotherapy response prediction.

As a member of ASCO, AACR, and SITC, Dr. Shu contributes to national cancer research initiatives while maintaining clinical practice in gastrointestinal oncology at the University of Maryland's NCI-designated cancer center.